PharmaEssentia Announces Licensing Agreement with WuXi Biologics for Antibody Development
Taiwan-based PharmaEssentia Corporation (TPE: 6446, FRA: 8Z1) has entered into a licensing agreement with China’s...
Taiwan-based PharmaEssentia Corporation (TPE: 6446, FRA: 8Z1) has entered into a licensing agreement with China’s...
Germany’s Boehringer Ingelheim (BI) has entered into a collaboration agreement with fellow German firm Zeiss...
The Guangdong Medicine Exchange has issued three notifications regarding the volume-based procurement (VBP) of medical...
US-based Cardinal Health (NYSE: CAH) has announced the acquisition of Swiss firm MedAlliance for a...
The government of the Hong Kong Special Administrative Region has entered into significant partnership agreements...
Everest Medicines (HKG: 1952), in partnership with Calliditas Therapeutics AB (Nasdaq: CALT), recently presented new...
Zhaoke Ophthalmology Ltd (HKG: 6622), a former subsidiary of Lee’s Pharmaceutical Holdings Ltd (HKG: 0950),...
Amicus Therapeutics (NASDAQ: FOLD), headquartered in the United States, has announced that it has received...
Singapore-based Vela Diagnostics, a global leader in integrated molecular solutions for diagnosing infectious diseases and...
China-based Transcenta Holding Ltd (HKG: 6628) has announced that it has received approval from the...
Shanghai’s healthcare security administration has announced a comprehensive set of measures aimed at enhancing community...
Global healthcare company Novo Nordisk (NYSE: NVO) and drug discovery alliance Evotec (NASDAQ: EVO) have...
Swiss pharmaceutical giant Roche (SWX: ROG) has announced the acquisition of global rights to develop,...
The US Food and Drug Administration (FDA) has granted Japan’s Takeda Pharmaceuticals (TYO: 4502) regulatory...
Neusoft Medical Systems Co., Ltd, a leading player in the medical technology sector, has announced...
CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has announced that it has received marketing...
China-based RemeGen Ltd (HKG: 9995) is poised to conduct a Phase II clinical study in...
US pharmaceutical major Eli Lilly (NYSE: LLY) has announced that it has received market approval...
Everest Medicines (HKG: 1952) has announced that it has received marketing approval for its antibiotic...
Sino Medical Sciences Technology Inc., (SHA: 688108), a leading Chinese medical device company, has announced...